Which has stronger valuation and earnings, ELDN or GANX?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A Gain Therapeutics N/A N/A -$20.16M -$0.58 N/A

Is ELDN or GANX more profitable?

Eledon Pharmaceuticals' return on equity of -116.97% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Gain Therapeutics N/A -201.44% -136.24%

Does the media prefer ELDN or GANX?

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 5 mentions for Eledon Pharmaceuticals and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.15 beat Eledon Pharmaceuticals' score of 0.57 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INDP or GANX?

Gain Therapeutics has a consensus price target of $7.50, indicating a potential upside of 328.57%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better earnings and valuation, INDP or GANX?

Gain Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A Gain Therapeutics N/A N/A -$20.16M -$0.58 N/A

Is INDP or GANX more profitable?

Gain Therapeutics' return on equity of -201.44% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% Gain Therapeutics N/A -201.44% -136.24%

Which has stronger earnings and valuation, GANX or NMRA?

Gain Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gain Therapeutics N/A N/A -$20.16M -$0.58 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A

Is GANX or NMRA more profitable?

Neumora Therapeutics' return on equity of -181.70% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Neumora Therapeutics N/A -181.70% -119.15%

Does the media favor GANX or NMRA?

In the previous week, Neumora Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Neumora Therapeutics and 3 mentions for Gain Therapeutics. Neumora Therapeutics' average media sentiment score of 1.21 beat Gain Therapeutics' score of 1.15 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ORGO or GANX?

In the previous week, Organogenesis and Organogenesis both had 3 articles in the media. Organogenesis' average media sentiment score of 1.49 beat Gain Therapeutics' score of 1.15 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GANX or CLLS more profitable?

Gain Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Cellectis -89.51% -80.66% -20.51%

Does the media prefer GANX or CLLS?

In the previous week, Gain Therapeutics had 1 more articles in the media than Cellectis. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Cellectis. Gain Therapeutics' average media sentiment score of 1.15 beat Cellectis' score of 1.08 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gain Therapeutics (GANX) Competitors

$1.75 -0.07 (-3.85%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.76 +0.00 (+0.29%)

As of 07/24/2026 07:34 PM Eastern

Compare

GANX vs. ELDN, INDP, NMRA, ORGO, and CLLS

Should you buy Gain Therapeutics stock or one of its competitors? MarketBeat compares Gain Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gain Therapeutics include Eledon Pharmaceuticals (ELDN), Indaptus Therapeutics (INDP), Neumora Therapeutics (NMRA), Organogenesis (ORGO), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry.

How does Gain Therapeutics compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 5 mentions for Eledon Pharmaceuticals and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.15 beat Eledon Pharmaceuticals' score of 0.57 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eledon Pharmaceuticals currently has a consensus price target of $9.67, suggesting a potential upside of 170.02%. Gain Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 328.57%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Eledon Pharmaceuticals' return on equity of -116.97% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Gain Therapeutics	N/A	-201.44%	-136.24%

Eledon Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market.

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.58	N/A

Summary

Gain Therapeutics beats Eledon Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Gain Therapeutics compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Gain Therapeutics has a consensus price target of $7.50, indicating a potential upside of 328.57%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Gain Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.58	N/A

In the previous week, Gain Therapeutics had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Indaptus Therapeutics. Gain Therapeutics' average media sentiment score of 1.15 beat Indaptus Therapeutics' score of 0.44 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Gain Therapeutics	Positive

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Indaptus Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market.

Gain Therapeutics' return on equity of -201.44% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Gain Therapeutics	N/A	-201.44%	-136.24%

Summary

Gain Therapeutics beats Indaptus Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Gain Therapeutics compare to Neumora Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Neumora Therapeutics' return on equity of -181.70% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Gain Therapeutics has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Neumora Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Neumora Therapeutics and 3 mentions for Gain Therapeutics. Neumora Therapeutics' average media sentiment score of 1.21 beat Gain Therapeutics' score of 1.15 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 328.57%. Neumora Therapeutics has a consensus price target of $6.57, suggesting a potential upside of 341.04%. Given Neumora Therapeutics' higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Gain Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.58	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Summary

Neumora Therapeutics beats Gain Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Gain Therapeutics compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Gain Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Gain Therapeutics	N/A	-201.44%	-136.24%

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Organogenesis has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market.

Organogenesis has higher revenue and earnings than Gain Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.58	N/A

In the previous week, Organogenesis and Organogenesis both had 3 articles in the media. Organogenesis' average media sentiment score of 1.49 beat Gain Therapeutics' score of 1.15 indicating that Organogenesis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis presently has a consensus target price of $5.75, suggesting a potential upside of 140.59%. Gain Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 328.57%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Organogenesis beats Gain Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Gain Therapeutics compare to Cellectis?

Gain Therapeutics (NASDAQ:GANX) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Gain Therapeutics currently has a consensus price target of $7.50, suggesting a potential upside of 328.57%. Cellectis has a consensus price target of $7.00, suggesting a potential upside of 146.48%. Given Gain Therapeutics' higher probable upside, equities research analysts plainly believe Gain Therapeutics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gain Therapeutics has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.58	N/A
Cellectis	$79.59M	3.58	-$67.59M	-$0.67	N/A

In the previous week, Gain Therapeutics had 1 more articles in the media than Cellectis. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Cellectis. Gain Therapeutics' average media sentiment score of 1.15 beat Cellectis' score of 1.08 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market. Comparatively, Cellectis has a beta of 2.88, meaning that its share price is 188% more volatile than the broader market.

Gain Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Cellectis	-89.51%	-80.66%	-20.51%

Summary

Gain Therapeutics and Cellectis tied by winning 8 of the 16 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GANX vs. The Competition

Export

Metric	Gain Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$77.63M	$3.07B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-3.02	20.29	27.14	23.64
Price / Sales	N/A	485.19	517.08	89.45
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	3.65	4.13	10.28	6.07
Net Income	-$20.16M	$65.94M	$3.60B	$331.99M
7 Day Performance	2.34%	-4.16%	-1.27%	-0.63%
1 Month Performance	1.74%	-3.76%	-0.37%	-2.00%
1 Year Performance	3.55%	9.94%	18.30%	13.62%

Gain Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GANX Gain Therapeutics	2.9102 of 5 stars	$1.75 -3.8%	$7.50 +328.6%	+4.2%	$77.63M	N/A	N/A	20
ELDN Eledon Pharmaceuticals	2.5545 of 5 stars	$4.05 +4.9%	$9.67 +138.7%	-4.0%	$297.95M	N/A	N/A	10	News Coverage Analyst Forecast
INDP Indaptus Therapeutics	0.3956 of 5 stars	$2.63 flat	N/A	-73.6%	$297.83M	N/A	N/A	6	Short Interest Increase Gap Up
NMRA Neumora Therapeutics	3.2959 of 5 stars	$1.58 -1.3%	$6.57 +315.9%	-34.9%	$296.45M	N/A	N/A	108	News Coverage Positive News Analyst Downgrade
ORGO Organogenesis	1.9437 of 5 stars	$2.34 +3.1%	$5.75 +145.7%	-49.7%	$292.09M	$564.17M	N/A	950	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GANX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gain Therapeutics (GANX) Competitors

GANX vs. ELDN, INDP, NMRA, ORGO, and CLLS

How does Gain Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Gain Therapeutics compare to Indaptus Therapeutics?

Summary

How does Gain Therapeutics compare to Neumora Therapeutics?

Summary

How does Gain Therapeutics compare to Organogenesis?

Summary

How does Gain Therapeutics compare to Cellectis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gain Therapeutics (GANX) Competitors

GANX vs. ELDN, INDP, NMRA, ORGO, and CLLS

How does Gain Therapeutics compare to Eledon Pharmaceuticals?

Does the media prefer ELDN or GANX?

Do insiders and institutionals have more ownership in ELDN or GANX?

Do analysts rate ELDN or GANX?

Is ELDN or GANX more profitable?

Which has more risk & volatility, ELDN or GANX?

Which has stronger valuation and earnings, ELDN or GANX?

Summary

How does Gain Therapeutics compare to Indaptus Therapeutics?

Do analysts rate INDP or GANX?

Which has better earnings and valuation, INDP or GANX?

Does the media prefer INDP or GANX?

Do institutionals & insiders hold more shares of INDP or GANX?

Which has more volatility & risk, INDP or GANX?

Is INDP or GANX more profitable?

Summary

How does Gain Therapeutics compare to Neumora Therapeutics?

Is GANX or NMRA more profitable?

Which has more risk and volatility, GANX or NMRA?

Do institutionals and insiders hold more shares of GANX or NMRA?

Does the media favor GANX or NMRA?

Do analysts rate GANX or NMRA?

Which has stronger earnings and valuation, GANX or NMRA?

Summary

How does Gain Therapeutics compare to Organogenesis?

Is ORGO or GANX more profitable?

Do institutionals & insiders have more ownership in ORGO or GANX?

Which has more risk & volatility, ORGO or GANX?

Which has stronger valuation and earnings, ORGO or GANX?

Does the media prefer ORGO or GANX?

Do analysts rate ORGO or GANX?

Summary

How does Gain Therapeutics compare to Cellectis?

Do analysts rate GANX or CLLS?

Do insiders & institutionals have more ownership in GANX or CLLS?

Which has better earnings & valuation, GANX or CLLS?

Does the media prefer GANX or CLLS?

Which has more volatility & risk, GANX or CLLS?

Is GANX or CLLS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools